Pregnant women with urinary tract infections (UTIs) caused by multidrug-resistant (MDR) bacteria may be at increased risk of developing pyelonephritis, according to a single-centre, retrospective study presented at SMFM 2020.
The administration of adjunctive azithromycin prior to unscheduled Caesarean sections may reduce post-surgical infection risk, according to a study presented at SMFM 2020.
A recent US-based study showed that the targeted synthetic (ts)DMARD* tofacitinib may not have a higher risk of serious infection compared with all biologic DMARDs (bDMARDs).
Many children in Singapore may not be vaccinated according to the national recommended immunization schedule, with maternal age, ethnicity, household income, and number of siblings among the factors influencing non-adherence, according to findings from the GUSTO* study.
Dolutegravir demonstrated noninferiority to low-dose efavirenz in antiretroviral (ART)-naïve patients with HIV-1 infection in a resource-limited setting, according to the NAMSAL ANRS 12313* study presented at IAS 2019.
The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.
Individuals with HIV-1 who demonstrate virologic suppression on a tenofovir alafenamide fumarate (TAF)-based three- or four-drug regimen (TBR) could safely switch to a two-drug regimen comprising dolutegravir and lamivudine, according to results from the phase III TANGO* study presented at the recent International AIDS Society conference (IAS 2019).